Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TUKTY
ADC Name
PRO1184
Synonyms
GEN1184; PRO 1184; PRO-1184; PRO1184; Rina-S; Rinatabart Sesutecan
   Click to Show/Hide
Organization
ProfoundBio (Suzhou) Co., Ltd.
Drug Status
Phase 3
Indication
In total 7 Indication(s)
Ovarian cancer
Phase 3
Clinical Trial
Breast cancer
Phase 2
Clinical Trial
Endometrial cancer
Phase 2
Clinical Trial
Fallopian tube cancer
Phase 2
Clinical Trial
Lung cancer
Phase 2
Clinical Trial
Melanoma
Phase 2
Clinical Trial
Peritoneal cancer
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Rinatabart
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Exatecan
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
Cys-11 ADC linker
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
sesutecan
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05579366
Phase 1/2
Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05579366  Clinical Status Phase 1/2
Clinical Description Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.
References
Ref 1 Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors, NCT05579366